Patients using compounded “wellness” peptides may lack reliable information on their safety and effectiveness, according to a joint white paper from ECRI and the Institute for Safe Medication Practices.
The groups said many peptides promoted for muscle building, anti-aging and recovery have not undergone adequate clinical evaluation and are not approved for human use. A federal policy change in April altered the regulatory classification of 12 peptides but was not supported by new clinical evidence, according to ECRI and the ISMP.
Evidence gaps remain significant. For BPC-157, 35 of 36 published studies were conducted in animals, with no phase 1 human safety data or controlled human efficacy trials. Testing of gray market products found purity ranging from 5% to 75%, along with contamination exceeding toxicity thresholds for injectable drugs.
ECRI and the ISMP also cited safety signals across the peptide class, including a halted clinical trial after a fatal cardiac event, case reports of melanoma and kidney dysfunction and a documented death following intravenous administration.
The groups said many patients obtain these products online without prescriptions, pharmacist oversight or quality testing. They recommended patients use only FDA-approved therapies and consult clinicians before use, while urging providers to counsel patients on risks.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
